Naranjargal Dashdorj
A5038328003- Hepatitis B Virus Studies
- Hepatitis C virus research
- Liver Disease Diagnosis and Treatment
- Blood Pressure and Hypertension Studies
- SARS-CoV-2 and COVID-19 Research
- Hepatitis Viruses Studies and Epidemiology
- Vaccine Coverage and Hesitancy
- Healthcare Systems and Public Health
- COVID-19 Clinical Research Studies
- Global Public Health Policies and Epidemiology
- Sodium Intake and Health
- Health Systems, Economic Evaluations, Quality of Life
- Healthcare Systems and Reforms
- Pharmaceutical Practices and Patient Outcomes
- COVID-19 epidemiological studies
- Climate Change and Health Impacts
- Chronic Lymphocytic Leukemia Research
- Animal Virus Infections Studies
- vaccines and immunoinformatics approaches
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Promotion and Cardiovascular Prevention
- Cervical Cancer and HPV Research
- Cytomegalovirus and herpesvirus research
- Neuroendocrine regulation and behavior
- Global Healthcare and Medical Tourism
Center for Digestive and Liver Diseases
2025
National Center for Communicable Diseases
2020-2022
Queen's Medical Centre
2008
University of Nottingham
2008
During the SARS-CoV-2 pandemic, novel and traditional vaccine strategies have been deployed globally. We investigated whether antibodies stimulated by mRNA vaccination (BNT162b2), including third-dose boosting, differ from those generated infection or adenoviral (ChAdOx1-S Gam-COVID-Vac) inactivated viral (BBIBP-CorV) vaccines. analyzed human lymph nodes after for correlates of serological differences. Antibody breadth against variants is lower compared with all vaccines evaluated but...
Abstract Despite notable scientific and medical advances, broader political, socioeconomic behavioural factors continue to undercut the response COVID-19 pandemic 1,2 . Here we convened, as part of this Delphi study, a diverse, multidisciplinary panel 386 academic, health, non-governmental organization, government other experts in from 112 countries territories recommend specific actions end persistent global threat public health. The developed set 41 consensus statements 57 recommendations...
Morbidity and mortality attributable to chronic hepatitis C virus (HCV) infection are increasing in many countries as the infected population ages. Models were developed for 15 quantify characterize viremic population, well estimate number of new infections HCV related deaths from 2013 2030. Expert consensus was used determine current treatment levels outcomes each country. In most countries, prevalence has already peaked. every country studied, begins decline before 2030, when held...
Summary Chronic hepatitis C virus ( HCV ) infection is a leading cause of liver related morbidity and mortality. In many countries, there lack comprehensive epidemiological data that are crucial in implementing disease control measures as new treatment options become available. Published literature, unpublished expert consensus were used to determine key parameters, including prevalence, viremia, genotype the number patients diagnosed treated. this study 15 viremic prevalence ranged from...
Hepatitis delta virus (HDV) causes the most severe form of human viral hepatitis. HDV requires a hepatitis B (HBV) coinfection to provide with HBV surface antigen envelope proteins. The net effect is make underlying disease worse, including higher rates hepatocellular carcinoma. Accurate assessments current prevalence have been hampered by lack readily available and reliable quantitative assays, combined absence Food Drug Administration-approved therapy. We sought develop convenient assay...
Different SARS-CoV-2 vaccines are approved in various countries, but few direct comparisons of the antibody responses they stimulate have been reported. We collected plasma specimens July 2021 from 196 Mongolian participants fully vaccinated with one four COVID-19 vaccines: Pfizer/BioNTech, AstraZeneca, Sputnik V, and Sinopharm. Functional testing a panel nine viral variant receptor binding domain (RBD) proteins revealed marked differences vaccine responses, low levels RBD-ACE2 blocking...
Abstract Background & Aims Chronic hepatitis D (delta) is a major global health burden. Clinical and virological characteristics of patients with virus ( HDV ) infection treatment approaches in different regions world‐wide are poorly defined. Methods The Hepatitis Delta International Network HDIN registry was established 2011 centres Europe, Asia, North‐ South America. Here, we report on clinical/ the first 1576 ongoing or past included database until October 2016 performed retrospective...
Summary The hepatitis C virus ( HCV ) epidemic was forecasted through 2030 for 15 countries, and the relative impact of two scenarios considered: (i) increased treatment efficacy while holding treated population constant (ii) annual population. Increasing levels diagnosis treatment, in combination with improved efficacy, were critical achieving substantial reductions disease burden. In most had to increase several fold achieve largest ‐related morbidity mortality. This suggests that capacity...
Summary In this study, a representative group of Mongolian adults was tested for hepatitis B virus ( HBV ) and C HCV ). Screening conducted at 17 different locations on randomly sampled group, representing the adult population. A total 1158 adults, 500 (43.1%) men 659 (56.9%) women were included. The prevalence estimates amongst general population found to be 11.1%±1% SE 8.5%±0.7% or 207 418 160 228 cases, respectively. For , majority cases are concentrated in older age groups with 25.8%...
Abstract Background InVITE (NCT# 05096091) is a 7-country observational study assessing immune responses to COVID-19 vaccines offered from national vaccination programs. This analysis focuses on the response 2 months after receipt of booster vaccine (third dose) among participants Mexico and Mongolia. Vaccines assessed were mRNA (Comirnaty, Pfizer (BioNTech), non-replicating viral vector (Vaxzevria, Oxford/AstraZeneca; Sputnik-V, Gam-COVID-Vac), or inactivated virus (CoronaVac, SinoVac...
Objectives Hepatitis delta virus (HDV) is the smallest human that causes most severe form of viral hepatitis. However, virus’s biological features, transmission routes and endemicity in particular populations are not yet fully understood. HDV shares hepatitis B (HBV) parenteral mode with HBV; therefore, sexual transmissions also possible. data on limited. Methods This study included 60 patients chronic HBV/HDV coinfection. The median age (IQR) was 35 (23–47) years, all were Mongolian....
<title>Abstract</title> <bold>Background & Aims</bold> Chronic hepatitis B/D is the most severe chronic hepatitis, yet public awareness of its burden remains low. This study examines prevalence viral among Mongol migrants in Sweden with possible linkage to care.<bold>Methods</bold> A screening event for was conducted on 28th − 29th January 2023 at Karolinska University Hospital, Stockholm individuals descent. Consented participants underwent blood tests and liver stiffness measurements....
Background Chronic hepatitis D (CHD) causes severe chronic hepatitis. Knowledge is limited about factors correlating with ALT in treatment-naive patients CHD. This study analyzed the prevalence and determinants of elevation a large cohort CHD, including young adults, compared to propensity score-matched (PSM) HBV mono-infected patients. Methods We identified 3,399 HBsAg+ adults CHD (HDV RNA positive) or 2,556 mono-infection attending liver center Mongolia during 2015-2023. The relation...
Early diagnosis of chronic hepatitis B virus (HBV) and C (HCV) infections is pivotal for optimal disease management. Sensitivity specificity 19 rapid diagnostic test (RDT) kits by different manufacturers (ABON, CTK Biotech, Cypress Diagnostics, Green Gross, Human Diagnostic, Humasis, InTec, OraSure, SD Bioline, Wondfo) were assessed on serum samples 270 Mongolians (90 seropositive surface antigen (HBsAg), 90 antibody (HCV-Ab), healthy subjects). All tested RDTs detection HBsAg performed with...
Cardiovascular disease (CVD) is the leading cause of mortality worldwide, with 80% that occurring in low- and middle-income countries. Hypertension, its primary risk factor, can be effectively addressed through multisectoral, multi-intervention initiatives. However, evidence for population-level impact on cardiovascular (CV) event rates mortality, cost-effectiveness such initiatives scarce as long-term longitudinal data often lacking. Here, we model population health a multisectoral urban...
Abstract Background The urban population health initiative was designed as a multidisciplinary, multisector programme to address cardiovascular (CV) disease, specifically hypertension and its underlying causes in the cities of Ulaanbaatar, Mongolia; Dakar, Senegal; São Paulo, Brazil. This article aims provide an overview history dynamics CV disease policy making three countries, present reform contributions role agenda-setting framework/process each country identify enablers challenges for...
We sought to estimate the prevalence of metabolic syndrome (MS) in urban population Mongolia and suggest a preferred definition. This cross-sectional study comprised 2076 representative samples, which were randomly selected provide blood samples. MS was defined by National Cholesterol Education Program’s Adults Treatment Panel III (NCEP ATP III), International Diabetes Federation (IDF), Joint Interim Statement (JIS). The Cohen’s kappa coefficient (κ) analyzed determine agreement between...
Nitrous oxide, in a concentration of 50% or more, is known cerebral vasodilator. This study investigated whether lower dose (30%) nitrous oxide would also increase blood flow. In addition, the authors wished to flow was accompanied by an metabolism.Multimodal Magnetic Resonance Imaging at 3T performed, and data were obtained 17 healthy volunteers during three inhalation conditions: medical air, oxygen-enriched air (40% oxygen), 30% with oxygen). Arterial spin labeling used derive primary...